BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 24452599)

  • 1. Heart rate reduction with ivabradine in patients with acute decompensated systolic heart failure.
    Sargento L; Satendra M; Longo S; Lousada N; dos Reis RP
    Am J Cardiovasc Drugs; 2014 Jun; 14(3):229-35. PubMed ID: 24452599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ivabradine therapy on heart failure biomarkers.
    Ordu S; Yildiz BS; Alihanoglu YI; Ozsoy A; Tosun M; Evrengul H; Kaftan HA; Ozhan H
    Cardiol J; 2015; 22(5):501-9. PubMed ID: 25733317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early NT-proBNP decrease with ivabradine in ambulatory patients with systolic heart failure.
    Sargento L; Satendra M; Longo S; Lousada N; Palma dos Reis R
    Clin Cardiol; 2013 Nov; 36(11):677-82. PubMed ID: 23929789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twenty-four-hour heart rate lowering with ivabradine in chronic heart failure: insights from the SHIFT Holter substudy.
    Böhm M; Borer JS; Camm J; Ford I; Lloyd SM; Komajda M; Tavazzi L; Talajic M; Lainscak M; Reil JC; Ukena C; Swedberg K
    Eur J Heart Fail; 2015 May; 17(5):518-26. PubMed ID: 25801408
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. I(f) current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life.
    Abdel-Salam Z; Rayan M; Saleh A; Abdel-Barr MG; Hussain M; Nammas W
    Cardiol J; 2015; 22(2):227-32. PubMed ID: 25179314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure.
    Cavusoglu Y; Mert U; Nadir A; Mutlu F; Morrad B; Ulus T
    J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):603-9. PubMed ID: 24922198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction.
    Gallet R; Ternacle J; Damy T; Guendouz S; Bremont C; Seemann A; Gueret P; Dubois-Rande JL; Lim P
    Int J Cardiol; 2014 Sep; 176(2):450-5. PubMed ID: 25129291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of heart rate in cardiovascular diseases: how the results of the BEAUTIFUL study change clinical practice.
    Bruguera Cortada J; Varela A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():9-12. PubMed ID: 20000882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score.
    Salah K; Kok WE; Eurlings LW; Bettencourt P; Pimenta JM; Metra M; Bayes-Genis A; Verdiani V; Bettari L; Lazzarini V; Damman P; Tijssen JG; Pinto YM
    Heart; 2014 Jan; 100(2):115-25. PubMed ID: 24179162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ivabradine: in adults with chronic heart failure with reduced left ventricular ejection fraction.
    Perry CM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):415-26. PubMed ID: 23181944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial.
    Böhm M; Swedberg K; Komajda M; Borer JS; Ford I; Dubost-Brama A; Lerebours G; Tavazzi L;
    Lancet; 2010 Sep; 376(9744):886-94. PubMed ID: 20801495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.
    Fischer-Rasokat U; Honold J; Lochmann D; Wolter S; Liebetrau C; Fichtlscherer S; Möllmann H; Spyridopoulos I; Hamm CW
    Clin Res Cardiol; 2016 Jun; 105(6):527-34. PubMed ID: 26687495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
    Zugck C; Martinka P; Stöckl G
    Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose?: findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study.
    Swedberg K; Komajda M; Böhm M; Borer J; Robertson M; Tavazzi L; Ford I;
    J Am Coll Cardiol; 2012 May; 59(22):1938-45. PubMed ID: 22617188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heart rate reduction with ivabradine and health related quality of life in patients with chronic heart failure: results from the SHIFT study.
    Ekman I; Chassany O; Komajda M; Böhm M; Borer JS; Ford I; Tavazzi L; Swedberg K
    Eur Heart J; 2011 Oct; 32(19):2395-404. PubMed ID: 21875859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy and safety analysis of ivabradine hydrochloride treatment of Chinese patients with chronic heart failure: subgroup analysis of Chinese patients in the SHIFT study].
    Hu DY; Huang DJ; Yuan ZY; Zhao RP; Yan XW; Wang MH;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2017 Mar; 45(3):190-197. PubMed ID: 28316174
    [No Abstract]   [Full Text] [Related]  

  • 18. Heart rate reduction for 12 months with ivabradine reduces left ventricular mass in cardiac allograft recipients.
    Doesch AO; Ammon K; Konstandin M; Celik S; Kristen A; Frankenstein L; Buss S; Hardt S; Sack FU; Katus HA; Dengler TJ
    Transplantation; 2009 Sep; 88(6):835-41. PubMed ID: 19920784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Ivabradine on Central Aortic Blood Pressure and Myocardial Perfusion in Patients With Stable Coronary Artery Disease.
    Dillinger JG; Maher V; Vitale C; Henry P; Logeart D; Manzo Silberman S; Allée G; Levy BI
    Hypertension; 2015 Dec; 66(6):1138-44. PubMed ID: 26418022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of ivabradine in patients with chronic systolic heart failure according to blood pressure level in SHIFT.
    Komajda M; Böhm M; Borer JS; Ford I; Robertson M; Manolis AJ; Tavazzi L; Swedberg K;
    Eur J Heart Fail; 2014 Jul; 16(7):810-6. PubMed ID: 24961493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.